Obesity Clinical Trial
Official title:
The Effects of Milk and Yogurt Supplementation on Bone Health, Body Composition, and Gut Microbiota in Canadian Young Adults: A Randomized Controlled Trial
Milk and dairy products contain significant amounts of nutrients that contribute to optimal health - nutrients like calcium, vitamin D, and high-quality protein. Fermented milk products or fermented dairy products are dairy foods that have been fermented with certain bacteria. Yogurt is a fermented dairy product containing millions of beneficial bacteria. In this study, the invesgitagtors will look at the effect of milk (a non-fermented dairy product) and yogurt (a fermented dairy product) supplementation on bone health and the amount of fat and muscle mass in Canadian young adults over a 24-month period. While dairy products contain significant amounts of nutrients, the scientific community does not know the impact of long-term supplementation of fermented (i.e., yogurt) or non-fermented (i.e., milk) dairy food on bone health and the amount of fat and muscle mass in young adults. To fill this knowledge gap, the investigators will recruit participants with low calcium intake and assign them to three different groups: 1) milk (intervention) group; 2) yogurt (intervention) group; and 3) control group. The investigators will ask the participants in the milk group to drink 1.5 servings (375 mL) of milk per day for 24 months. Participants in the yogurt group will consume 2 servings (350 g) of yogurt per day for 24 months. Those in the control group will continue their usual diets. Using a randomized controlled trial design, the investigators will measure bone health parameters, hormonal indices related to bone metabolism, body composition (e.g., muscle mass, fat mass), and the number and composition of bacteria living in the gastrointestinal (GI) tract. The hypothesis is that supplementation with yogurt will have more positive effects on bone health indices, particularly femoral neck BMD as the primary outcome, than milk in Canadian adults aged 19-30 years. The secondary hypothesis is that supplementation with yogurt, as a fermented milk product, will have a more beneficial effect than milk on body composition measures. The data will provide valuable information for developing targeted health initiatives and marketing strategies regarding the benefits of fermented and non-fermented dairy product consumption.
Status | Not yet recruiting |
Enrollment | 99 |
Est. completion date | May 15, 2028 |
Est. primary completion date | May 1, 2027 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 19 Years to 30 Years |
Eligibility | Inclusion Criteria: - 19-30 years old - Dietary calcium intake below 1000mg/ day - living in the Saskatoon area (Saskatchewan, Canada) Exclusion Criteria: - Calcium intake from both food and supplement above the estimated average requirement (EAR) for adults aged 19-30 years (>800 mg/day) - Total dairy intake of more than 1 serving per day - Body mass index greater than to 30 kg/m2 - Medical history of metabolic bone, liver, endocrine, connective tissue, and respiratory diseases, thyroid disorders, or cancer - Diagnosed cases with secondary osteoporosis due to hypoparathyroidism - Hormonal disorders or disturbances - Taking medications known to influence bone mass and density (e.g., steroids, diuretics, heparin, and cancer drugs) - Cow's milk allergy - Pregnant or lactating women, or those planning to conceive during the duration of the trial |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Saskatchewan | Agriculture and Agri-Food Canada, Dairy Farmers of Canada |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Bone structure | Measurement via HR-pQCT scan at distal radius and tibia | Baseline, month 12, month 24 | |
Other | Bone geometry | Measurement via HR-pQCT scan at distal radius and tibia | Baseline, month 12, month 24 | |
Other | Serum bone alkaline phosphatase (biochemical indices of bone turnover) | Fasting blood sample will be collected from each participant between 8 a.m. and 10 a.m. after an overnight fast of 12 hours with no heavy exercise/workouts 48 hours prior to blood collection into 2 x 4ml serum separating tubes (SST) for the analysis of all serum measures. | Baseline, month 12, month 24 | |
Other | Serum osteocalcin (biochemical indices of bone turnover) | Fasting blood sample will be collected from each participant between 8 a.m. and 10 a.m. after an overnight fast of 12 hours with no heavy exercise/workouts 48 hours prior to blood collection into 2 x 4ml serum separating tubes (SST) for the analysis of all serum measures. | Baseline, month 12, month 24 | |
Other | Serum procollagen type 1 N-propeptide (biochemical indices of bone turnover) | Fasting blood sample will be collected from each participant between 8 a.m. and 10 a.m. after an overnight fast of 12 hours with no heavy exercise/workouts 48 hours prior to blood collection into 2 x 4ml serum separating tubes (SST) for the ananalysis of all serum measures. | Baseline, month 12, month 24 | |
Other | Serum N-terminal telopeptide of type 1 collagen (biochemical indices of bone turnover) | Fasting blood sample will be collected from each participant between 8 a.m. and 10 a.m. after an overnight fast of 12 hours with no heavy exercise/workouts 48 hours prior to blood collection into 2 x 4ml serum separating tubes (SST) for the analysis of all serum measures. | Baseline, month 12, month 24 | |
Other | Serum C-terminal telopeptide of type 1 collagen (biochemical indices of bone turnover) | Fasting blood sample will be collected from each participant between 8 a.m. and 10 a.m. after an overnight fast of 12 hours with no heavy exercise/workouts 48 hours prior to blood collection into 2 x 4ml serum separating tubes (SST) for the aanalysis of all serum measures. | Baseline, month 12, month 24 | |
Other | Serum PTH (hormonal indices related to bone metabolism) | Fasting blood samples will be collected from each participant between 8 a.m. and 10 a.m. after an overnight fast of 12 hours with no heavy exercise/workouts 48 hours prior to blood collection for the analysis of all serum measures. | Baseline, month 12, month 24 | |
Other | Serum 25(OH)D (hormonal indices related to bone metabolism) | Fasting blood samples will be collected from each participant between 8 a.m. and 10 a.m. after an overnight fast of 12 hours with no heavy exercise/workouts 48 hours prior to blood collection for the analysis of all serum measures. | Baseline, month 12, month 24 | |
Other | Serum IGF-1 (hormonal indices related to bone metabolism) | Fasting blood samples will be collected from each participant between 8 a.m. and 10 a.m. after an overnight fast of 12 hours with no heavy exercise/workouts 48 hours prior to blood collection for the analysis of all serum measures. | Baseline, month 12, month 24 | |
Other | Saliva IGF-1 (hormonal indices related to bone metabolism) | Saliva samples will be collected from each participant for analysis of salivary IGF-1 and comparison to serum IGF-1. | Baseline, month 12, month 24 | |
Other | Fat mass and lean mass | Measurement via Dual Energy X-ray Absorptiometry. | Baseline, month 12, month 24 | |
Other | Height | Height (cm) in standing position will be measured to the nearest 0.1 cm by a wall-mounted stadiometer. | Baseline, month 12, month 24 | |
Other | Weight | For weight measurements, participants will be asked to wear light clothes and remove their shoes and jewelry and then stand on the SECA electronic scale to measure the weight to the nearest 0.01 kg. | Baseline, month 12, month 24 | |
Other | Gut microbiota via general lactobacillus and bifdobacterium | Stool samples will be collected using DNAgenotek Omnigene sample collection kits and the total DNA of gut microbiomes from fecal material will be extracted using QIAamp PowerFecal Pro DNA Kit (Cat No. 51804), following manufacturer's instructions | Baseline, month 12, month 24 | |
Other | Dietary assessment | Dietary intake will be assessed using serial 24-hour dietary recalls. Dietary data will be collected in person at baseline, 12 months, and 24 months and via telephone at 6 months and 18 months. The mean of three 24-h recalls at each time point will provide an estimation of the usual intake. | Baseline, month 6, month 12, month 18, month 24 | |
Other | Physical activity | Physical activity will be captured using the Physical Activity Adult Questionnaire (PAAQ) to include transportation, recreational, and occupational or household physical activity in the last 7 days. | Baseline, month 6, month 12, month 18, month 24 | |
Primary | Femoral neck bone mineral density | Measurement will be done via Dual Energy X-ray Absorptiometry. | Baseline, month 12, month 24 | |
Secondary | Bone mineral density (total hip, lumbar spine, whole body) | Measurement will be done via Dual Energy X-ray Absorptiometry. | Baseline, month 12, month 24 | |
Secondary | Bone mineral content (total hip, femoral neck, lumbar spine, whole body) | Measurement will be done via Dual Energy X-ray Absorptiometry. | Baseline, month 12, month 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |